Research Compound
FOXO4
FOXO4-DRI is a synthetic D-retro-inverso peptide based on the FOXO4 transcription factor sequence, available as a lyophilized powder for laboratory research.
Select Size
10mg
SKU: FOXO4
Batch: 202512-01-FOXO4
$215.99
Ships today if ordered by 4PM EST
Est. Arrival: 09/18/2026
Volume Discounts
Qty: 1 - 4$215.99 each
Qty: 5 - 9$194.39 each(save $21.60)
Qty: 10+$172.79 each(save $43.20)
Quantity:
1
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
99%+ Purity
COA Included
Fast Shipping
USA Based
Product Details
FOXO4-DRI is designed using D-retro-inverso (DRI) approach: reversed sequence with all L-amino acids replaced by D-enantiomers. Maintains similar side chain topology while increasing proteolytic stability.
Derived from FOXO4 (Forkhead box O4) transcription factor sequence. FOXO4 belongs to forkhead family with conserved DNA-binding domain. D-amino acid peptides exhibit enhanced stability. Store at -20°C.
Disclaimer: For laboratory and research purposes only. Not intended for human consumption.
Frequently Asked Questions About FOXO4
Answers summarize published research and are provided for laboratory research purposes only.
The FOXO4 product from Biotech Compounds is FOXO4-DRI, a synthetic D-retro-inverso peptide based on a sequence from the FOXO4 forkhead transcription factor. Research studies have examined FOXO4-DRI primarily in the field of cellular senescence, where it has been used as a tool to selectively target senescent cells in cell culture and mouse models. It is supplied as a lyophilized powder for laboratory research.
In senescent cells, the FOXO4 transcription factor binds the tumor suppressor p53 and keeps it in the nucleus, which research has reported keeps the senescent cell from undergoing apoptosis. In vitro studies have shown that the FOXO4-DRI peptide competes for that interaction, releasing p53 so that the senescent cell can enter programmed cell death. Researchers describe this as a senolytic mechanism.
The primary research area for FOXO4 in its DRI peptide form is senescence biology and aging research. In mouse models, researchers reported that clearing senescent cells with FOXO4-DRI was associated with changes in tissue function and physical measures in aged animals. Published research uses FOXO4-DRI as a chemical tool to test whether senescent cell accumulation drives specific age-related changes.
Secondary research areas for FOXO4-DRI include chemotherapy-induced senescence, where animal models have been used to examine whether removing senescent cells changes recovery after chemotherapy exposure, and the broader study of FOXO family transcription factors. Researchers also study the D-retro-inverso design of FOXO4 as a general strategy for building protease-resistant peptide tools.
The evidence for FOXO4-DRI comes from in vitro cell culture experiments and mouse model studies published in the peer-reviewed literature. It has not been evaluated in clinical trials and remains an investigational research compound. Biotech Compounds supplies FOXO4 in the DRI form so laboratories can continue to study these reported findings under controlled conditions.
FOXO4-DRI and Epitalon are both used in aging research but act on entirely different targets. FOXO4-DRI is a large D-amino acid peptide that research has reported disrupts the FOXO4 and p53 interaction to trigger apoptosis in senescent cells. Epitalon is a tiny four-residue bioregulator studied for telomerase activity and pineal function. Both are available from Biotech Compounds as lyophilized powders for laboratory research.
FOXO4-DRI uses a D-retro-inverso design, meaning the sequence is reversed and every L-amino acid is replaced with its D-enantiomer. This keeps the side chain topology similar to the native FOXO4 sequence while making the peptide resistant to proteases. Research has shown that D-amino acid peptides remain intact far longer than L-peptides in biological fluids, which is why the DRI form is used.
FOXO4-DRI is supplied as a lyophilized powder. Allow the vial to reach room temperature before opening, then add Bacteriostatic Water or sterile water slowly against the inner wall of the vial. Swirl gently until the solution is clear and never shake. Because the FOXO4 peptide is relatively large, it may take a little longer to dissolve than a short peptide, so patience with gentle swirling is preferred.
Store the sealed lyophilized FOXO4-DRI vial at -20 C, protected from light and moisture. After reconstitution, keep the solution refrigerated at 2 to 8 C, protect it from light, and avoid repeated freeze thaw cycles. The D-amino acid structure of FOXO4-DRI gives it strong resistance to enzymatic breakdown, but cold storage is still required to preserve the peptide in solution.
Yes. FOXO4-DRI from Biotech Compounds is supplied at 99 percent or greater purity. Each lot is third-party tested for identity and purity, and the Certificate of Analysis is available on the product page. Researchers can confirm the analytical results before using the FOXO4 peptide in a senescence assay.
FOXO4-DRI has a molecular weight of approximately 4909 g/mol and the molecular formula C203H313N55O61S. It is a synthetic peptide built entirely from D-amino acids in retro-inverso order relative to the native FOXO4 forkhead sequence. FOXO4 itself belongs to the forkhead box O family of transcription factors, which share a conserved DNA-binding domain.
No. FOXO4-DRI is sold by Biotech Compounds strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 or older. The FOXO4 peptide is not a drug or dietary supplement, has not been approved by any regulatory agency, and is not for human or animal consumption.
You May Also Like
